On October 20, 2023, the FDA approved PENBRAYA, a meningococcal conjugate vaccine targeting meningococcal serogroups A, B, C, Y, and W-135. This vaccine was approved in individuals between the ages of 10 and 25 years, to be given intramuscularly at a two-dose series administered at least six months apart.
The CDC’s ACIP voted on October 25, 2023 to recommend the use of PENBRAYA in healthy individuals aged 16 to 23 years and high-risk individuals aged 10 and older who are recommended to receive meningococcal A, C, Y and W-135 vaccine (MenACWY) and meningococcal B vaccine (MenB) at the same visit.
